Direct Antilymphoma Effects on Human Lymphoma Cells of Monotherapy and Combination Therapy with CD20 and HLA-DR Antibodies and 90Y-Labeled HLA-DR Antibodies

Autor: Kaylund Chan, Evan Tobin, Bonnie M. Bradt, Sally J. DeNardo, Gerald L. DeNardo

Publikováno v: Clinical Cancer Research. 11:7075s-7079s

Purpose: Monoclonal antibodies (mAb) in combination and mAbs combined with a radionuclide (radioimmunotherapy) have both been more effective in patients than mAb monotherapy.Experimental Design: Using assays of cell growth and viability, the dose res

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::443d0fdf1edf58a0451094f281bd9d4a
https://doi.org/10.1158/1078-0432.ccr-1004-0008

Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines

Autor: Gerald L. DeNardo, Alan L. Epstein, Nan Zhang, Evan Tobin, Sally J. DeNardo, Cathy Liu

Publikováno v: Tobin, Evan; Denardo, Gerald; Zhang, Nan; Epstein, Alan L; Liu, Cathy; & Denardo, Sally. (2007). Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines. Leukemia & Lymphoma, 48(5), 944-956. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/8pk1f4nx

Rituximab is effective in about one half of patients with indolent lymphoma. Even these patients relapse and develop rituximab resistance. To increase potency and circumvent resistance, the anti-lymphoma effects of rituximab, an anti-CD20 MAb(1), com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9934ae320b0357a4ef8bad85bd8b63e8
https://pubmed.ncbi.nlm.nih.gov/17487739